Chembio Diagnostics, Inc.
(NASDAQ CM: CEMI)
Rigrodsky Law, P.A. is investigating Chembio Diagnostics, Inc. (“Chembio”) regarding possible breaches of fiduciary duties and other violations of law related to Chembio’s agreement to be acquired by Biosynex SA. Under the terms of the agreement, Chembio’s shareholders will receive $0.45 per share in cash.